Zimmer Biomet Holdings Inc. (NYSE:ZBH) reached a new 52-week high during mid-day trading on Friday . The stock traded as high as $124.96 and last traded at $124.75, with a volume of 564,088 shares. The stock had previously closed at $122.02.

ZBH has been the topic of several recent analyst reports. Goldman Sachs Group Inc. cut their price objective on shares of Zimmer Biomet Holdings from $113.00 to $111.00 in a report on Friday, April 8th. Oppenheimer Holdings Inc. reiterated a “buy” rating on shares of Zimmer Biomet Holdings in a report on Saturday, April 30th. Morgan Stanley reiterated a “buy” rating on shares of Zimmer Biomet Holdings in a report on Saturday, April 30th. Barclays PLC reiterated a “buy” rating on shares of Zimmer Biomet Holdings in a report on Saturday, April 30th. Finally, Jefferies Group reiterated a “buy” rating and set a $129.00 price objective on shares of Zimmer Biomet Holdings in a report on Thursday, March 24th. One analyst has rated the stock with a sell rating, four have issued a hold rating and eighteen have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $124.50.

The company has a 50-day moving average price of $119.82 and a 200-day moving average price of $108.51. The firm has a market capitalization of $24.88 billion and a PE ratio of 307.61.

Zimmer Biomet Holdings (NYSE:ZBH) last announced its quarterly earnings results on Thursday, April 28th. The company reported $2.00 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.93 by $0.07. The firm earned $1.90 billion during the quarter, compared to the consensus estimate of $1.88 billion. The company’s quarterly revenue was up 67.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.54 EPS. On average, analysts forecast that Zimmer Biomet Holdings Inc. will post $7.96 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, July 29th. Investors of record on Friday, June 24th will be paid a $0.24 dividend. The ex-dividend date of this dividend is Wednesday, June 22nd. This represents a $0.96 annualized dividend and a dividend yield of 0.77%.

In related news, CFO Daniel P. Florin sold 12,000 shares of the business’s stock in a transaction that occurred on Tuesday, April 12th. The stock was sold at an average price of $110.00, for a total value of $1,320,000.00. Following the completion of the sale, the chief financial officer now owns 38,415 shares of the company’s stock, valued at approximately $4,225,650. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Daniel P. Florin sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, April 14th. The shares were sold at an average price of $114.98, for a total value of $1,149,800.00. Following the completion of the sale, the chief financial officer now directly owns 28,415 shares of the company’s stock, valued at approximately $3,267,156.70. The disclosure for this sale can be found here.

Other large investors have recently made changes to their positions in the company. Whittier Trust Co. purchased a new stake in shares of Zimmer Biomet Holdings during the fourth quarter valued at approximately $1,022,000. Liberty Mutual Group Asset Management Inc. bought a new stake in Zimmer Biomet Holdings during the fourth quarter valued at $1,029,000. Amica Mutual Insurance Co. bought a new stake in Zimmer Biomet Holdings during the fourth quarter valued at $1,064,000. Commerzbank Aktiengesellschaft FI bought a new stake in Zimmer Biomet Holdings during the fourth quarter valued at $1,104,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new stake in Zimmer Biomet Holdings during the fourth quarter valued at $1,147,000.

Zimmer Biomet Holdings, Inc, formerly Zimmer Holdings, Inc, is engaged designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.